GRB10 and cancer: The testing of the three imprinted gene panel on 1013 clinical samples, including 260 normal and benign, and 753 malignant cases from bladder, breast, colorectal, esophageal, gastric, lung, pancreatic, prostate, skin, and thyroid cancers demonstrated how the expression status of GNAS, GRB10, and SNRPN significantly changed in cancer cases versus their normal and benign tissue controls.